Stomach Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years old, of any gender
• People with advanced cancer that cannot be cured — including stomach cancer, esophageal cancer, cervical cancer, triple-negative breast cancer, non-small cell lung cancer, or other cancers — where standard treatments have stopped working, the cancer has come back, or the person cannot tolerate current treatment options
• People who have tumor tissue or cancer-related fluid (from the chest or abdomen) available to be collected for the trial, meeting specific size or cell count requirements, from a site that has not previously been treated with oncolytic virus therapy
• People who still have at least one measurable area of cancer remaining after the tissue collection procedure
• People with a good general health and activity level, rated 0 or 1 on the ECOG scale (confirm with trial site)
• People with an expected survival of more than 3 months
• People whose recent blood test results (taken within 14 days before tissue collection) show that blood cell counts, kidney function, liver function, and clotting ability are within acceptable ranges as defined by the trial
• People whose urine protein levels are within acceptable limits on recent testing
• People whose heart pumping function, measured by an echocardiogram (heart ultrasound), shows the heart ejecting at least 50% of its blood volume per beat
• People whose lung function tests and blood oxygen levels meet the trial's minimum requirements
• Women of childbearing potential who have a negative pregnancy test at screening and who agree to use highly effective contraception for at least one year after receiving the treatment
• Male participants whose partners could become pregnant, who agree to use effective contraception and not donate sperm for at least one year after treatment
• People who have no medical reasons preventing them from having surgery or a needle biopsy procedure
• People who have stopped all cancer treatments — including radiotherapy, chemotherapy, hormonal therapy, targeted therapy, tumour embolisation, or herbal/traditional medicine with anti-cancer indications — at least 7 days before tissue collection
• People who are willing to give written informed consent and are able to follow the trial's visit schedule and procedures

Who may not be able to join:

• People with a known allergy to cyclophosphamide, fludarabine, interleukin-2, or any component of the treatment infusion, or to other medications used during the study such as certain antibiotics, human serum albumin, or dextran 40
• People who previously had to permanently stop an immunotherapy treatment due to a severe immune-related side effect (grade 3 or higher on the NCI CTCAE 5.0 scale)
• People with a pre-existing primary immune deficiency condition or an active autoimmune disease
• People who have previously had an organ transplant from another person, a stem cell transplant from another person, or kidney dialysis/replacement therapy
• People with current or past irreversible scarring or damage to the lung tissue (interstitial lung disease), unless it was caused by radiotherapy
• People currently diagnosed with two or more separate cancers — with exceptions for certain cancers that have been fully treated and have been in remission for more than 5 years, such as certain skin cancers, in-situ cervical cancer, bladder, breast, or thyroid cancer (confirm with trial site)
• People with uncontrolled high blood pressure, or who have had a stroke, mini-stroke, heart attack, or unstable chest pain in the 6 months before treatment; or who have severe heart failure, a low heart pumping rate, or serious heart rhythm problems
• People with certain high-risk vein problems in the oesophagus or stomach that may carry a high risk of bleeding, or signs of high blood pressure in the liver's blood vessels, who have not had a recent endoscopy assessment (confirm with trial site)
• People with uncontrolled metabolic conditions such as poorly controlled diabetes, or other serious non-cancer illnesses that could increase medical risk or make it harder to assess outcomes
• People with serious liver conditions, including hepatic encephalopathy (brain problems caused by liver failure), hepatorenal syndrome (kidney failure linked to liver disease), or severe cirrhosis (Child-Pugh grade C or worse)
• People with uncontrolled fluid build-up in body cavities (such as the chest or abdomen) that cannot be managed by drainage before joining the trial
• People with other serious physical organ disease or serious mental illness
• People with cancer that has spread to the brain or central nervous system
• People with an active, uncontrolled infection anywhere in the body
• People who have received a vaccination within 2 months before signing the consent form, or who plan to receive a vaccination during the trial
• People currently participating in, or who have participated in within the past 30 days, another clinical trial of a drug or biological therapy — with possible exceptions for certain fully cleared cell therapies (confirm with trial site)
• People who have used corticosteroids (such as prednisone above a low daily dose) or other immune-suppressing medications within 4 weeks before treatment, or who have a condition that would require such medications during the trial
• People who have had surgery, interventional procedures, radiotherapy, chemotherapy, or immunotherapy for their cancer within 2 weeks before the planned treatment
• People who are HIV positive, who test positive for syphilis, or who have active hepatitis B or C, or are carriers of hepatitis B or C viruses
• People who are pregnant or breastfeeding
• People who are unlikely to be able to follow the trial schedule and requirements due to personal, family, social, or geographic circumstances
• People who the trial investigators consider unsuitable for any other reason

Important: Always verify eligibility with the trial site directly before applying.